Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)

Ioka, Tatsuya; Kanai, Masashi; Kobayashi, Shogo; Sakai, Daisuke; Eguchi, Hidetoshi; Baba, Hideo; Seo, Satoru; Taketomi, Akinobu; Takayama, Tadatoshi; Yamaue, Hiroki; Takahashi, Masahiro; Sho, Masayuki; Kamei, Keiko; Fujimoto, Jiro; Toyoda, Masanori; Shimizu, Junzo; Goto, Takuma; Shindo, Yoshitaro; Yoshimura, Kenichi; Hatano, Etsuro; Nagano, Hiroaki; Hepatobiliary Oncology Group (KHBO), Kansai

doi:10.1002/jhbp.1219

Public

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

Published in Journal of Hepato-Biliary-Pancreatic Sciences • Jul 28, 2022

Authors:

Tatsuya Ioka

Masashi Kanai

Shogo Kobayashi

Abstract

BACKGROUND: Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past decade. In our previous phase II tr...

Subject

Gemcitabine

Medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!